The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

In Brief

PhRMA members invested $58.8 billion in R&D in 2015

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA’s member companies invested an estimated $58.8 billion in research and development in 2015, up 10.3 percent from 2014, based on the 2016 PhRMA annual member survey published in the 2016 Biopharmaceutical Research Industry Profile.

According to PhRMA, the biopharmaceutical industry is the most research-intensive sector of the U.S. economy, investing on average six times more in R&D as a percentage of sales than all other manufacturing industries.

The sector also accounted for an estimated 17 percent of all U.S. business R&D spending, the largest share of R&D spending by U.S. businesses. From 2000 to 2015, more than 550 new medicines were approved by FDA, including a record 56 new medicines in 2015.

Table of Contents

YOU MAY BE INTERESTED IN

Regulatory News

Makary vows to speed up drug approvals and end FDA’s “cozy” relationship with industry
Commissioner promises to protect scientific integrity while bringing in “fresh” MAHA ideas

In his first sit-down interview since beginning his role as FDA commissioner 17 days earlier, Marty Makary, a former Johns Hopkins surgeon and the only Trump pick for HHS whose confirmation received Democratic support, said he would speed up approvals for rare-disease treatments by reducing reliance on animal testing and shifting towards organoids and computational models. 
By Claire Marie Porter
Guest Editorial

Regulation must keep up with scientific advances

The American Cancer Society’s recent report on the increasing incidence rates of colorectal cancer in young adults once again rang an alarm bell for adults over 45 to get checked, especially if they are having symptoms. But as an oncologist with more than 40 years of experience, I also believe that this should be a clarion call to scientists and researchers, and for regulators at the FDA.
By Richard M. Goldberg
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account